List of Excipients in Branded Drug KYLEENA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bayer HealthCare Pharmaceuticals Inc	KYLEENA	levonorgestrel	50419-424	BARIUM SULFATE
Bayer HealthCare Pharmaceuticals Inc	KYLEENA	levonorgestrel	50419-424	DIMETHICONE

Kyleena Excipient Strategy and Commercial Opportunities

Last updated: August 14, 2026

Kyleena is a levonorgestrel-releasing intrauterine system marketed by Bayer. Its commercial differentiation depends less on conventional pharmaceutical excipients than on a controlled-release drug-device architecture: a levonorgestrel-loaded silicone reservoir, a silicone rate-controlling membrane, and a polyethylene intrauterine frame. The highest-value opportunities are in medical-grade silicone processing, low-variability reservoir manufacturing, extractables and leachables control, sterilization compatibility, and next-generation hormone-releasing intrauterine systems.

What excipients and device materials are used in Kyleena?

Kyleena contains 19.5 mg of levonorgestrel and releases the hormone locally over up to five years. The FDA labeling identifies the principal non-active materials as silicone elastomer, silica, polyethylene, barium sulfate, polypropylene, and silver components used within the intrauterine system structure.[1]

Component	Primary function	Commercial relevance
Silicone elastomer	Forms the drug reservoir and rate-controlling membrane	Controls levonorgestrel diffusion and requires medical-device-grade processing
Silica	Reinforces silicone elastomer	Affects mechanical strength, cure behavior, and drug-release consistency
Polyethylene	Forms the T-shaped frame	Requires biocompatibility, dimensional stability, and radiopacity integration
Barium sulfate	Provides radiopacity in the polyethylene frame	Requires controlled particle dispersion and process uniformity
Polypropylene	Used in removal threads	Must meet mechanical strength and biocompatibility specifications
Silver	Used as a marker in the vertical stem	Supports radiographic identification and product differentiation
Levonorgestrel	Active pharmaceutical ingredient	Must remain uniformly distributed in the silicone matrix

The term “excipient” has a narrower meaning in Kyleena than in an oral tablet or injectable. Several materials are integral device constituents rather than freely dispersed formulation excipients. Their regulatory assessment covers drug quality, device biocompatibility, chemical characterization, mechanical performance, and long-term release behavior.

How does Kyleena’s silicone drug-release system work?

Kyleena uses a matrix-reservoir system. Levonorgestrel is incorporated into a silicone elastomer core, which is surrounded by a silicone membrane that regulates diffusion into the uterine cavity.[1]

The release rate is controlled by several variables:

1. Levonorgestrel loading and particle distribution.
2. Silicone crosslink density.
3. Membrane thickness and uniformity.
4. Drug solubility and diffusion through the elastomer.
5. Reservoir surface area.
6. Manufacturing temperature, cure time, and pressure.
7. Aging and sterilization effects.

Kyleena releases levonorgestrel at approximately 17.5 micrograms per day after 24 days, with declining release over time. The system is approved for contraception for up to five years.[1]

This design creates a narrow process window. Small changes in silicone viscosity, silica loading, cure kinetics, membrane thickness, or drug particle size can alter the release profile. The commercial advantage is sustained local delivery without daily administration. The manufacturing disadvantage is that a supplier change can trigger extensive comparability, stability, and performance testing.

What excipient strategies are most important for Kyleena?

Medical-grade silicone selection

Silicone is the central material in the Kyleena release system. A suitable grade must support:

• Consistent levonorgestrel diffusion.
• Low extractables and leachables.
• Long-term implantation.
• Sterilization stability.
• Controlled tensile and tear strength.
• Reproducible curing.
• Low lot-to-lot variability.

Potential suppliers compete on platinum-cured silicone systems, medical-device documentation, raw-material traceability, and technical support. The strongest commercial position is held by suppliers that can provide a validated formulation and process package rather than commodity silicone alone.

Silica reinforcement

Silica improves the strength and processing characteristics of silicone elastomer. Its particle size, surface treatment, moisture content, and dispersion affect the final reservoir properties.

Silica suppliers can create value through:

• Narrow particle-size distributions.
• Low-metal and low-moisture grades.
• Improved dispersion in silicone.
• Consistent surface chemistry.
• Documentation for implantable-device use.

A silica change can affect both mechanical properties and drug-release kinetics. That makes silica a potential critical material even when its concentration is low.

Levonorgestrel dispersion

Uniform API distribution is essential. Agglomeration can create local concentration differences, alter release rates, and increase batch rejection risk.

Manufacturing opportunities include:

• Micronized levonorgestrel with controlled particle morphology.
• Surface-modified API particles.
• Improved powder wetting in silicone.
• In-line imaging or spectroscopy for content uniformity.
• Low-shear blending methods that limit particle segregation.

An API supplier with particle-engineering capability may have greater strategic value than a supplier offering only compendial levonorgestrel.

Polyethylene and radiopaque filler

The polyethylene frame must preserve shape during insertion, remain stable in the uterus, and provide adequate radiopacity. Barium sulfate dispersion affects imaging and mechanical integrity.

Commercial opportunities include:

• Medical-grade polyethylene compounds with controlled flexural properties.
• Improved barium sulfate dispersion.
• Lower-defect injection molding.
• Traceable compound systems.
• Processing support for thin, high-strength frame components.

Material changes to the frame can affect insertion force, device positioning, imaging, and patient experience. These changes therefore face a higher validation burden than ordinary packaging-material substitutions.

What manufacturing and intellectual-property barriers protect Kyleena?

Kyleena’s competitive protection is likely distributed across the active ingredient, release architecture, device geometry, manufacturing process, and clinical use rather than concentrated in a single conventional formulation patent.

What patents protect Kyleena?

Relevant patent categories include:

Patent category	Protected subject matter	Strategic effect
Drug-device architecture	Hormone reservoir integrated into an intrauterine frame	Creates design-around barriers
Controlled-release formulation	Levonorgestrel dispersed in silicone elastomer	Protects release kinetics and formulation composition
Membrane design	Silicone membrane thickness, geometry, or permeability	Limits substitute material strategies
Device structure	Frame shape, arms, marker, threads, and insertion configuration	Protects user handling and placement
Manufacturing methods	Molding, loading, curing, assembly, and testing	Raises process-transfer costs
Method of use	Contraceptive use and treatment-related indications	May affect labeling and litigation risk

A precise live-claim analysis requires review of the current FDA Orange Book, USPTO Patent Center, assignment records, and relevant court dockets. The FDA-approved label does not identify every patent that may affect a commercial launch.

What is the Orange Book status of Kyleena?

Kyleena was approved under NDA 208224 in September 2016.[1] Its five-year new chemical entity exclusivity period would have expired in 2021, subject to any applicable pediatric extension or other regulatory adjustments. Kyleena is a non-biologic drug-device combination, so biosimilar exclusivity does not apply.

The main regulatory question for a competing product is not whether levonorgestrel is known. It is whether a competitor can demonstrate pharmaceutical equivalence, bioequivalence or an accepted alternative standard, device equivalence, comparable release, and safe intrauterine performance through the applicable FDA pathway.

When does Kyleena lose exclusivity?

Kyleena’s statutory NCE exclusivity ended approximately five years after its September 2016 approval. Patent protection may extend beyond regulatory exclusivity, depending on the scope and term of issued patents, patent-term adjustment, patent-term extension, terminal disclaimers, and any listed patents associated with NDA 208224.

The practical loss-of-exclusivity timeline is therefore determined by the latest enforceable barrier, not by the NCE date alone.

Milestone	Approximate timing	Commercial significance
FDA approval	September 2016	Start of U.S. commercial life
NCE exclusivity	Approximately September 2021	Regulatory barrier ended
Five-year labeled use	2021 onward	Supports repeat replacement demand
Patent-controlled entry window	Patent-specific	Depends on live claims and litigation
Generic or follow-on entry	Pathway-specific	Requires drug and device comparability

Kyleena’s five-year duration supports a recurring replacement market. A patient using the system continuously may require replacement approximately every five years, creating a predictable installed-base opportunity for Bayer and future suppliers.

What generic entry risks exist for Kyleena?

Generic entry is more difficult than for an oral levonorgestrel product because Kyleena combines a drug with an implantable delivery system.

Paragraph IV challenges

A potential ANDA applicant could challenge listed patents through a Paragraph IV certification. The principal risk areas would include:

• Anticipation or obviousness of the silicone reservoir design.
• Non-infringement through a different membrane or frame configuration.
• Invalidity based on prior intrauterine systems.
• Failure of patent claims to cover the proposed product.
• Challenges to the scope or validity of method-of-use claims.

A Paragraph IV filing would expose the applicant to potential patent litigation and could trigger a 30-month stay if statutory conditions were met.[2]

505(b)(2) and alternative pathways

A 505(b)(2) application may be attractive if the product differs materially from Kyleena while relying partly on existing levonorgestrel safety information. The applicant could pursue a modified release profile, frame design, duration, or manufacturing approach.

The tradeoff is that a modified product may avoid some patent claims but require additional clinical, pharmacokinetic, local-tolerance, or device-performance data. A close copy may reduce development risk but increase infringement exposure.

Biosimilar risk

Kyleena has no biosimilar risk because levonorgestrel is a small-molecule hormone and the product is not a biologic. The relevant competitive threats are generic, hybrid, authorized-generic, and branded follow-on intrauterine systems.

What formulation patents and method-of-use patents matter?

Formulation patents may cover:

• Levonorgestrel concentration in the silicone matrix.
• Silicone composition and crosslinking chemistry.
• Drug particle size or distribution.
• Membrane thickness.
• Release-rate ranges.
• Reservoir dimensions.
• Stability characteristics.

Method-of-use patents may cover:

• Contraception for up to five years.
• Use in specific patient populations.
• Placement, replacement, or removal protocols.
• Use in patients with particular reproductive or clinical characteristics.

Method-of-use protection is commercially weaker when a generic can market the product with a permitted label that omits the protected indication or instruction. Device and formulation claims are often more important for a Kyleena-like product because they can apply directly to the physical product.

What commercial opportunities exist in Kyleena-related excipients?

High-value material supply

The most attractive suppliers provide qualified materials with a regulatory package covering:

• United States Pharmacopeia or equivalent testing.
• ISO 10993 biocompatibility data.
• Extractables and leachables profiles.
• Sterilization compatibility.
• Change-control commitments.
• Multi-year supply continuity.
• Lot traceability.
• Technical support during validation.

A supplier with only a low price is unlikely to displace a validated implantable-device material without a significant cost or performance advantage.

Contract manufacturing

Contract manufacturers can target:

• Silicone-drug compounding.
• Reservoir extrusion or molding.
• Membrane application.
• Frame injection molding.
• Automated assembly.
• In-process release testing.
• Sterile packaging.
• Shelf-life and accelerated-aging studies.

The strongest opportunity is integrated manufacturing. Separately supplying silicone, API, or polyethylene creates less differentiation than controlling a validated end-to-end process.

Analytical and quality services

Testing companies can support:

• Levonorgestrel content uniformity.
• In-vitro release testing.
• Silicone cure-state analysis.
• Mechanical testing.
• Radiopacity testing.
• Particulate characterization.
• Extractables and leachables.
• Sterilization residuals.
• Packaging integrity.
• Long-term stability.

Release testing is especially valuable because the product is designed to deliver a low daily dose over several years. Small analytical errors can create large uncertainty in the projected in-vivo performance.

Next-generation intrauterine systems

Platform extensions could target:

• Seven-year or longer duration.
• Lower insertion force.
• Smaller frame dimensions.
• Improved insertion ergonomics.
• Alternative hormones.
• Non-hormonal payloads.
• Reduced systemic exposure.
• Patient-controlled or clinician-assisted removal.
• Digital tracking of placement and replacement dates.

A new system using the same silicone technology could reduce development risk. A system using a different polymer or reservoir architecture could offer stronger patent differentiation but would require more extensive biocompatibility and release validation.

How does Kyleena compare with Mirena and Liletta?

Attribute	Kyleena	Mirena	Liletta
Active ingredient	Levonorgestrel	Levonorgestrel	Levonorgestrel
Initial total drug content	19.5 mg	52 mg	52 mg
Labeled duration	Up to five years at original approval; label should be checked for current indication	Longer-duration labeling has expanded over time	Duration has expanded over time
Primary positioning	Lower-dose hormonal IUD	Higher-dose contraception and therapeutic positioning	Value-oriented hormonal IUD
Release-system strategy	Silicone reservoir and membrane	Silicone-based levonorgestrel delivery system	Silicone-based levonorgestrel delivery system
Competitive distinction	Smaller, lower-dose platform	Larger installed base and broader clinical positioning	Lower-cost and access-oriented positioning

Kyleena’s commercial position is strongest where patients and clinicians value a smaller, lower-dose system. Mirena has greater brand recognition and broader indication history. Liletta competes more directly on access and price. The three products rely on similar broad technology concepts, but their device dimensions, drug loads, release rates, manufacturing specifications, labeling, and patent estates differ.

What is the revenue exposure and market opportunity?

Bayer reports women’s health products within broader business segments rather than consistently disclosing Kyleena revenue as a separate line item. Product-specific revenue exposure therefore cannot be inferred from Bayer’s consolidated reporting alone.[3]

The commercial opportunity has four components:

1. New insertions.
2. Replacement procedures after the labeled duration.
3. Geographic expansion.
4. Follow-on products that improve price, duration, insertion, or tolerability.

For excipient and component suppliers, the addressable market is smaller than the finished-drug market but can produce durable revenue because validated implantable materials are difficult to replace. Supplier economics improve when the same silicone, polymer, or analytical platform supports multiple intrauterine systems.

What geographic coverage applies to Kyleena?

Kyleena has been marketed in the United States and other jurisdictions under Bayer’s regulatory and commercial infrastructure. Patent coverage, regulatory exclusivity, device classification, and approved duration vary by country.

Key geographic issues include:

• U.S. NDA and Orange Book status.
• European Union centralized or national authorization status.
• National patent validation and supplementary protection rights.
• Local medical-device requirements.
• Import controls for implantable materials.
• Country-specific tender pricing.
• Reimbursement and contraceptive-access programs.

A supplier seeking international growth should prioritize materials with a global implantable-device documentation package. A component accepted in the United States may still require country-specific technical files, sterilization records, or chemical characterization data.

Key Takeaways

• Kyleena is a levonorgestrel drug-device combination, not a conventional tablet formulation.
• Silicone elastomer is the central release-controlling material.
• Silica, polyethylene, barium sulfate, polypropylene, and silver support mechanical, radiographic, or handling functions.
• The highest-value excipient opportunities involve qualified medical-grade materials, not commodity supply.
• Manufacturing know-how, release testing, biocompatibility, and change control create substantial barriers to substitution.
• Kyleena’s five-year NCE exclusivity ended approximately in 2021, but patent-specific barriers may continue beyond that date.
• Biosimilar competition does not apply. Generic and 505(b)(2) pathways are the relevant entry routes.
• Patent risk is likely concentrated in the reservoir, membrane, device geometry, manufacturing process, and method-of-use claims.
• Bayer does not consistently disclose Kyleena revenue as a standalone public reporting category.
• The most promising commercial opportunities are next-generation intrauterine systems, implantable silicone platforms, and integrated contract manufacturing.

FAQs

Can a different silicone elastomer avoid Kyleena patent claims?

Possibly, but a substitute material must still achieve comparable drug release, mechanical performance, sterilization stability, and implant biocompatibility. A material change may avoid a composition claim while remaining exposed to broader device or manufacturing claims.

Is levonorgestrel itself a commercial barrier to Kyleena competition?

No. Levonorgestrel is an established small-molecule API. The main barriers are controlled delivery, device performance, manufacturing reproducibility, regulatory evidence, and patent scope.

Are silicone excipients in Kyleena regulated like pharmaceutical excipients?

They are evaluated as part of an implantable drug-device system. The regulatory file must address chemical characterization, biocompatibility, mechanical performance, manufacturing controls, and drug-release behavior.

Could an excipient supplier sell the same silicone formulation to a Kyleena competitor?

Contractual confidentiality, exclusivity, intellectual-property rights, and regulatory change-control obligations may restrict reuse. The supplier must also avoid transferring proprietary process knowledge embedded in a customer-specific formulation.

What is the strongest follow-on product opportunity to Kyleena?

A smaller or lower-insertion-force system with a longer duration and comparable contraceptive effectiveness offers the clearest commercial differentiation. A lower-cost system using validated silicone-release technology offers the lowest development-risk path.

References

1. U.S. Food and Drug Administration. (2024). Kyleena levonorgestrel-releasing intrauterine system: Prescribing information. Bayer HealthCare Pharmaceuticals Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

3. Bayer AG. (2024). Annual report 2023. Bayer AG.